Oligonucleotides – Enabling the Future of Nucleic Acid Therapeutics
The rise of nucleic acid therapeutics — including antisense oligonucleotides, siRNA, mRNA, and splice modulators — has put short synthetic DNA/RNA strands at the forefront of precision medicine. These therapies offer enormous potential for oncology, rare diseases, and genetic disorders, yet success depends as much on high-purity ingredients, robust delivery systems, and regulatory compliance as on molecular design.
At DKSH, our Oligonucleotide Solutions combine nucleosides, derivatives, phosphoramidites, liposomes, and advanced delivery excipients to provide a reliable backbone for oligonucleotide R&D and commercial development.
Key Challenges Across the Oligonucleotide Value Chain
| Industry Pressures & Key Questions | Ingredient Solutions from DKSH | How It Helps |
| How can we ensure ultra-high purity in nucleoside synthesis to minimize off-target effects? | Nucleosides & Nucleoside Derivatives | Serve as the critical precursors for oligo synthesis. DKSH provides GMP-grade, impurity-profiled nucleosides that ensure sequence fidelity and reduce risks of mutations. |
| How can oligonucleotides be delivered safely across biological barriers? | Liposomes, Nanoparticles, PEG-Conjugates, Advanced Delivery Systems | Improve cellular uptake, stability in plasma, and reduce immunogenicity. Lipid nanoparticles (LNPs) are already proven in mRNA vaccines — DKSH provides high-quality excipients to build these systems. |
| How do we maintain stability during scale-up and downstream purification? | Nucleoside Derivatives, Buffers & Salts | Controlled impurities and formulation-ready buffers support stability, desalting, and large-batch processing without quality compromise. |
| How do we prepare for regulatory scrutiny in multiple global markets? | Full Regulatory Documentation & Compliance Support | All supplied materials align with GMP/ICH standards, supported with CoAs, impurity profiles, and validated supply chains to accelerate approval processes. |
Delivery Systems: The Critical Enabler
While oligonucleotide design continues to evolve rapidly, the biggest barrier remains getting these molecules into the right cells, intact and functional. Naked oligonucleotides face rapid degradation, poor bioavailability, and immune activation.
| Key Delivery Challenges | Ingredient Solutions from DKSH |
|
|
DKSH’s Integrated Capabilities
- Full coverage: nucleosides, derivatives, phosphoramidites, liposomes, nanoparticles, delivery excipients.
- Available from milligram-scale (R&D) to kilogram-scale (commercial manufacturing).
- Expertise in oligo-lipid conjugates and lipid nanoparticle design.
- Pilot-scale assistance to reduce formulation risks.
- Multiple validated supplier sources to mitigate risks from geopolitical disruptions and tariffs.
- Regional/local stocking from North America to Europe and Asia-Pacific
- Compliance with GMP/ICH standards.
- Support for FDA, EMA, and APAC filings.
Strategic Outlook
Oligonucleotides are one of the fastest-growing therapeutic classes worldwide, but their success depends on much more than sequence design. High-purity ingredients and advanced delivery systems are now the real differentiators between a promising molecule and a viable medicine.
DKSH provides a holistic ingredient and application ecosystem, empowering innovators to scale their nucleic acid therapies with confidence, compliance, and reduced risk.
Looking Ahead
Are you ready to take your nucleic acid therapy pipeline to the next level?
Discover DKSH’s comprehensive oligonucleotide solutions, including nucleosides, phosphoramidites, derivatives, and advanced delivery systems here. Let us help you accelerate your next-gen therapeutic development with confidence and compliance.
